Baxter Presents Data at EAHAD from Long-Term Outcomes Registry Reinforcing Prophylaxis Treatment Experience with ADVATE Baxter International Inc. today presented clinical data on Baxter’s leading recombinant factor VIII treatment, including interim data from the first year of observation from the AHEAD study, a four-year outcomes registry of hemophilia A patients treated with ADVATE [Antihemophilic Factor Plasma/Albumin-Free Method].
Feb. 27, 2014 - Business Wire via Yahoo! Finance